Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Laurie Ballew

Psychiatry Paducah, KY Doctor of Osteopathy

NPI 1639141948 CMS profile 28402

2520 New Holt Rd Ste I, Paducah, KY 42001

Open in the dashboard

General payments

$3,404

188 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laurie Ballew of Paducah, KY is reported in the CMS Open Payments database as having received $3,404 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $926 52
2024 General $824 44
2023 General $403 25
2022 General $549 23
2021 General $293 19
2020 General $124 8
2019 General $285 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laurie Ballew
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Laurie Ballew were reported at $926. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Laurie Ballew Psychiatry median Middle half National median
2019 $285 $184 $59–$605 $163
2020 $124 $119 $36–$372 $114
2021 $293 $143 $43–$576 $132
2022 $549 $153 $50–$590 $149
2023 $403 $170 $56–$651 $160
2024 $824 $179 $57–$673 $164
2025 $926 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $436 7 payments
  2. AbbVie, Inc. $431 32 payments
  3. Otsuka America Pharmaceutical, Inc. $356 20 payments
  4. Lundbeck LLC $344 22 payments
  5. Alkermes, Inc. $255 13 payments
  6. E.R. Squibb & Sons, L.L.C. $229 14 payments
  7. Janssen Pharmaceuticals, Inc $223 13 payments
  8. Neurocrine Biosciences, Inc. $200 11 payments
  9. Teva Pharmaceuticals USA, Inc. $152 9 payments
  10. ITI, Inc. $128 8 payments
  11. Other $651 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,221 186 payments
  2. Debt forgiveness $155 1 payment
  3. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR $380 29 payments
  2. REXULTI Psychiatry $319 18 payments
  3. NEUROSTAR TMS THERAPY SYSTEM $268 5 payments
  4. REXULTI Psychiatry $213 16 payments
  5. SPRAVATO $206 12 payments
  6. ARISTADA Cns $203 11 payments
  7. ARISTADA Cns $203 11 payments
  8. ARISTADA Cns $203 11 payments
  9. ARISTADA Cns $203 11 payments
  10. LYBALVI $177 10 payments
  11. Other $2,218 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

2,170

Median for Psychiatry: 574

Drug cost

$220,506

Median for Psychiatry: $27,624

Branded share of claims

28.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 37 $62,822
Trintellix Vortioxetine Hydrobromide Brand 73 $52,175
Rexulti Brexpiprazole Brand 24 $40,047
Vyvanse Lisdexamfetamine Dimesylate Brand 66 $24,035
Eliquis Apixaban Brand 13 $7,601
Lisdexamfetamine Dimesylate Generic 42 $7,373
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 151 $3,934
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 84 $3,406
Oxcarbazepine Generic 39 $1,240
Olanzapine Generic 46 $1,221

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$205,852

Medicare's payments for the services billed

Medicare patients

236

Average age 60

Services billed

2,421

165 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 74%
High blood pressure 64%
Arthritis 43%
Diabetes 23%
COPD 19%
Chronic kidney disease 17%
Ischemic heart disease 16%
Heart failure 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $155
$155 37 —
REXULTI
  • Lundbeck LLC $48
  • Otsuka America Pharmaceutical, Inc. $34
$82 24 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $56
$56 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $49
$49 — —
Auvelity
  • Axsome Therapeutics, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record